Voleon Capital Management LP Purchases New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Voleon Capital Management LP purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 37,181 shares of the biopharmaceutical company’s stock, valued at approximately $8,749,000. Alnylam Pharmaceuticals accounts for about 0.6% of Voleon Capital Management LP’s holdings, making the stock its 29th largest position.

Several other large investors have also recently bought and sold shares of the business. Allworth Financial LP boosted its holdings in shares of Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 38 shares during the period. Nixon Peabody Trust Co. grew its position in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 43 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares during the period. Nwam LLC raised its position in shares of Alnylam Pharmaceuticals by 5.8% during the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 50 shares during the last quarter. Finally, National Bank of Canada FI lifted its position in shares of Alnylam Pharmaceuticals by 9.0% in the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 55 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ALNY shares. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a “buy” rating and a $353.00 target price on the stock. Chardan Capital restated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Sanford C. Bernstein cut their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $315.58.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the sale, the chief marketing officer now directly owns 13,537 shares in the company, valued at approximately $3,454,236.29. The trade was a 10.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock valued at $1,875,627 in the last quarter. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $257.19 on Wednesday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market cap of $33.46 billion, a PE ratio of -118.52 and a beta of 0.30. The stock has a 50-day moving average of $247.55 and a 200-day moving average of $255.64. Alnylam Pharmaceuticals, Inc. has a one year low of $143.81 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.